Total submissions: 6
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Eurofins Ntd Llc |
RCV000401799 | SCV000342222 | uncertain significance | not provided | 2016-05-22 | criteria provided, single submitter | clinical testing | |
Genomic Research Center, |
RCV000662053 | SCV000784389 | uncertain significance | Autosomal recessive ataxia, Beauce type | 2018-03-05 | criteria provided, single submitter | clinical testing | |
Al Jalila Children’s Genomics Center, |
RCV001731565 | SCV001984603 | uncertain significance | not specified | 2020-03-19 | criteria provided, single submitter | clinical testing | |
Labcorp Genetics |
RCV002519299 | SCV002980067 | uncertain significance | Autosomal recessive ataxia, Beauce type; Emery-Dreifuss muscular dystrophy 4, autosomal dominant | 2023-04-05 | criteria provided, single submitter | clinical testing | In summary, the available evidence is currently insufficient to determine the role of this variant in disease. Therefore, it has been classified as a Variant of Uncertain Significance. An algorithm developed to predict the effect of missense changes on protein structure and function (PolyPhen-2) suggests that this variant  is likely to be tolerated. ClinVar contains an entry for this variant (Variation ID: 288185). This variant has not been reported in the literature in individuals affected with SYNE1-related conditions. This variant is present in population databases (rs202121741, gnomAD 0.009%). This sequence change replaces alanine, which is neutral and non-polar, with threonine, which is neutral and polar, at codon 7165 of the SYNE1 protein (p.Ala7165Thr). |
Revvity Omics, |
RCV000401799 | SCV003826340 | uncertain significance | not provided | 2020-02-18 | criteria provided, single submitter | clinical testing | |
Department of Pathology and Laboratory Medicine, |
RCV000401799 | SCV001553956 | uncertain significance | not provided | no assertion criteria provided | clinical testing | The SYNE1 p.Ala7236Thr variant was not identified in the literature nor was it identified in LOVD 3.0. The variant was identified in dbSNP (ID: rs202121741) and ClinVar (classified as uncertain significance by EGL Genetics and Genomic Research Center, Shahid Beheshti University of Medical Sciences). The variant was also identified in control databases in 15 of 282616 chromosomes at a frequency of 0.00005308 (Genome Aggregation Database March 6, 2019, v2.1.1). The variant was observed in the following populations: Other in 1 of 7214 chromosomes (freq: 0.000139), European (non-Finnish) in 12 of 128962 chromosomes (freq: 0.000093) and South Asian in 2 of 30616 chromosomes (freq: 0.000065), but was not observed in the African, Latino, Ashkenazi Jewish, East Asian, or European (Finnish) populations. The p.Ala7236 residue is conserved in mammals but not in more distantly related organisms however four out of five computational analyses (PolyPhen-2, SIFT, AlignGVGD, BLOSUM, MutationTaster) do not suggest a high likelihood of impact to the protein; this information is not predictive enough to rule out pathogenicity. The variant occurs outside of the splicing consensus sequence and in silico or computational prediction software programs (SpliceSiteFinder, MaxEntScan, NNSPLICE, GeneSplicer) do not predict a difference in splicing. In summary, based on the above information the clinical significance of this variant cannot be determined with certainty at this time. This variant is classified as a variant of uncertain significance. |